[ADMP] Adamis Pharmaceuticals Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.85 Change: 0.15 (5.56%)
Ext. hours: Change: 0 (0%)

chart ADMP

Refresh chart

Strongest Trends Summary For ADMP

ADMP is in the long-term down -92% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company?s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.86
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-80.02% ROE-94.54% ROI
Current Ratio2.58 Quick Ratio Long Term Debt/Equity Debt Ratio0.18
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10.64 M Cash From Investing Activities Cash From Operating Activities-3.17 M Gross Profit
Net Profit-3.14 M Operating Profit-4.15 M Total Assets20.01 M Total Current Assets11.32 M
Total Current Liabilities2.28 M Total Debt Total Liabilities2.28 M Total Revenue
Technical Data
High 52 week5.65 Low 52 week1.84 Last close1.9 Last change3.26%
RSI41.67 Average true range0.12 Beta0.35 Volume88.65 K
Simple moving average 20 days-5.24% Simple moving average 50 days-11.02% Simple moving average 200 days-45.1%
Performance Data
Performance Week-3.06% Performance Month-0.52% Performance Quart-56.32% Performance Half-39.2%
Performance Year-58.7% Performance Year-to-date-55.81% Volatility daily3.66% Volatility weekly8.19%
Volatility monthly16.79% Volatility yearly58.16% Relative Volume256.82% Average Volume388.73 K
New High New Low

News

2019-11-12 19:05:12 | Adamis Pharmaceuticals ADMP Reports Q3 Loss, Misses Revenue Estimates

2019-11-12 16:28:05 | Adamis Pharmaceuticals Announces Third Quarter 2019 Financial Results and Business Update

2019-11-07 08:54:01 | Implied Volatility Surging for Adamis Pharmaceuticals ADMP Stock Options

2019-11-06 16:05:00 | Adamis Pharmaceuticals Schedules Third Quarter 2019 Earnings Conference Call and Business Update

2019-11-05 06:53:31 | The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

2019-11-04 20:00:00 | Adamis Pharmaceuticals Provides Regulatory Update for Its Higher Dose Naloxone Pre-Filled Syringe

2019-11-01 10:30:02 | Will Adamis Pharmaceuticals ADMP Report Negative Q3 Earnings? What You Should Know

2019-10-18 06:26:52 | Could The Adamis Pharmaceuticals Corporation NASDAQ:ADMP Ownership Structure Tell Us Something Useful?

2019-10-08 09:00:00 | Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting

2019-10-01 09:00:00 | Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand

2019-09-26 09:00:00 | Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting

2019-09-12 06:20:54 | Adamis Pharmaceuticals Corporation NASDAQ:ADMP: What Does Its Beta Value Mean For Your Portfolio?

2019-09-03 09:00:00 | Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate

2019-08-28 09:00:00 | Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI

2019-08-26 16:05:00 | Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors

2019-08-14 09:00:00 | Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary

2019-08-09 13:35:56 | Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMT

2019-08-08 20:40:12 | Adamis Pharmaceuticals ADMP Reports Q2 Loss, Misses Revenue Estimates

2019-08-08 16:30:00 | Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

2019-08-07 06:38:46 | Did Changing Sentiment Drive Adamis Pharmaceuticals's NASDAQ:ADMP Share Price Down A Painful 73%?

2019-08-05 09:00:00 | Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update

2019-08-02 10:30:02 | Adamis Pharmaceuticals ADMP May Report Negative Earnings: Know the Trend Ahead of Q2 Release

2019-08-01 09:00:00 | Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants

2019-07-31 16:05:00 | Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

2019-07-26 09:13:01 | Will Flagship Impella Drive ABIOMED's ABMD Q1 Earnings?

2019-07-26 09:12:01 | Masimo MASI to Report Q2 Earnings: What's in the Offing?

2019-07-25 07:37:11 | What's in the Offing for DexCom's DXCM Earnings in Q2?

2019-07-24 09:00:00 | Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals

2019-07-18 13:52:31 | Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.

2019-07-09 08:30:00 | Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI

2019-07-09 07:45:02 | Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

2019-06-27 09:00:00 | Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.

2019-06-20 10:02:22 | Have Insiders Been Selling Adamis Pharmaceuticals Corporation NASDAQ:ADMP Shares?

2019-06-11 09:00:00 | Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product

2019-05-21 08:30:00 | Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product

2019-05-14 09:00:00 | Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product

2019-05-10 14:02:01 | Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT

2019-05-09 17:55:09 | Adamis Pharmaceuticals ADMP Reports Q1 Loss, Misses Revenue Estimates

2019-05-09 16:51:19 | Adamis: 1Q Earnings Snapshot

2019-05-09 16:30:00 | Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

2019-05-07 09:00:00 | Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

2019-05-02 10:32:02 | Adamis Pharmaceuticals ADMP May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-03-15 16:39:50 | Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update

2019-03-15 07:39:26 | The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

2019-03-14 16:55:00 | Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate

2019-03-14 10:30:02 | Adamis Pharmaceuticals ADMP May Report Negative Earnings: Know the Trend Ahead of Q4 Release

2019-03-13 11:51:10 | Before You Buy Adamis Pharmaceuticals Corporation NASDAQ:ADMP, Consider Its Volatility

2019-02-27 08:13:48 | The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

2019-02-26 18:54:40 | Adamis Provides Regulatory Update on Sublingual Tadalafil

2019-02-20 09:00:00 | Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic